- Home
- FFIV vs ILMN Comparison
FFIV vs ILMN Comparison
Compare FFIV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIV
- ILMN
- Stock Information
- Founded
- FFIV 1996
- ILMN 1998
- Country
- FFIV United States
- ILMN United States
- Employees
- FFIV N/A
- ILMN N/A
- Industry
- FFIV Computer Communications Equipment
- ILMN Medical Specialities
- Sector
- FFIV Telecommunications
- ILMN Health Care
- Exchange
- FFIV Nasdaq
- ILMN Nasdaq
- Market Cap
- FFIV 16.9B
- ILMN 16.9B
- IPO Year
- FFIV 1999
- ILMN 2000
- Fundamental
- Price
- FFIV $307.43
- ILMN $94.66
- Analyst Decision
- FFIV Hold
- ILMN Buy
- Analyst Count
- FFIV 11
- ILMN 17
- Target Price
- FFIV $314.90
- ILMN $126.71
- AVG Volume (30 Days)
- FFIV 533.7K
- ILMN 2.4M
- Earning Date
- FFIV 07-30-2025
- ILMN 07-31-2025
- Dividend Yield
- FFIV N/A
- ILMN N/A
- EPS Growth
- FFIV 22.06
- ILMN N/A
- EPS
- FFIV 11.34
- ILMN 7.91
- Revenue
- FFIV $3,024,656,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- FFIV $9.69
- ILMN N/A
- Revenue Next Year
- FFIV $4.21
- ILMN $2.78
- P/E Ratio
- FFIV $27.10
- ILMN $11.97
- Revenue Growth
- FFIV 8.94
- ILMN N/A
- 52 Week Low
- FFIV $184.81
- ILMN $68.70
- 52 Week High
- FFIV $334.00
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- FFIV 59.47
- ILMN 42.41
- Support Level
- FFIV $294.89
- ILMN $92.25
- Resistance Level
- FFIV $334.00
- ILMN $111.00
- Average True Range (ATR)
- FFIV 6.74
- ILMN 4.03
- MACD
- FFIV 0.64
- ILMN -0.74
- Stochastic Oscillator
- FFIV 41.27
- ILMN 13.13
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.